Drug handling by the aging liver: Past work and future directions

Reviews in Clinical Gerontology

Volumn 6, Issue 3, 1996, Pages 215-223

  Woodhouse, Ken ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME;

AGED; AGING; DRUG ELIMINATION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ENZYME INDUCTION; HUMAN; LIVER; LIVER BLOOD FLOW; MORPHOLOGY; PHYSIOLOGY; REVIEW; STRESS;

EID: 0029967015     PISSN: 09592598     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0959259800004718     Document Type: Review

References (88)

1. Office of Health Economics (OHE). OHW Briefing No. 13: Effect of prescription charges. London: OHE, 1980.
2. Skoll SL, August RJ, Johnson GE. Drug prescribing for the elderly in Saskatchewan during 1976. Can Med Assoc J 1979; 121: 1074.
3. Guttman D. Patterns of legal drug use by older Americans. Addict Dis Int J 1978; 3: 337.
4. Schmucker DL. Age-related changes in drug disposition. Pharmacol Rev 1979; 30: 445-56.
5. Greenblatt DJ, Sellars EM, Shader RI. Drug disposition in old age. N Engl J Med 1982; 306: 1081-88.
6. Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev 1985; 37: 133-48.
7. Woodhouse KW, James OFW. Hepatic drug metabolism and ageing. Br Med Bull 1990; 46: 22-35.
8. O'Mahony MS, Woodhouse KW. Age, environmental factors and drug metabolism. Pharmacol Ther 1994; 61: 279-87.
9. Williams RT. Comparative patterns of drug metabolism. Fed Proc 1967; 26: 1029-39.
10. Vessell ES. The antipyrine test in clinical pharmacology: conceptions of misconceptions. Clin Pharmacol Ther 1979; 26: 275-86.
11. Stevenson IH. Factors influencing antipyrine elimination. Br J Clin Pharmacol 1977; 4: 261-65.
12. O'Malley K, Crooks J, Duke E et al. Effect of age and sex on human drug metabolism. BMJ 1971; 3: 607-609.
13. Greenblatt DJ, Divoll MK, Harmatz JS et al. Antipyrine absorption and disposition in the elderly. Pharmacology 1988; 36: 125-33.
14. Wood AJJ, Vestal RE, Wilkinson GR et al. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther 1979; 26: 16-20.
15. Hartleb M. Drugs and the liver. II. The role of the antipyrine test in drug metabolism studies. Biopharm Drug Dispos 1991; 12: 559-70.
16. Posner J, Danhof M, Teunissen MWE, Breimer DD, Whitieman PP. The disposition of antipyrine and its metabolites in young and elderly healthy volunteers. Br J Clin Pharmacol 1987; 24: 51-56.
17. Wynne HA, Cope LH, James OFW, Rawlins MD, Woodhouse KW. The effect of age and frailty upon acetanilide clearance. Age Ageing 1989; 18: 415-18.
18. Greenblatt DJ, Sellers EM, Shade RI. Drug disposition in old age. N Engl J Med 1982; 306: 1081-88.
19. Nation RL, Learoyd B, Barber J, Triggs EJ. The pharmacokinetics of chlormethiazole following intravenous administration in the aged. Ear J Clin Pharmacol 1976; 10: 407-15.
20. Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981; 6: 389-96.
21. Robertson DRC, Waller DG, Renwick AG, George CF. Age-related changes in the pharmaco-kinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297-305.
22. Jackson SHD, Johnston A, Wollard R, Turner P. The relationship between theophylline clearance and age in adult life. Eur J Pharmacol 1989; 36: 29-34.
23. Sorstein L, Larsen A, Midtbo K, Saevareid L. Pharmacokinetics of calcium channel blockers in patients with renal insufficiency and in geriatric patients. Acta Med Scand 1984; 681 (suppl 2): 25-30.
24. Hunt CM, Westerkam SR, Stave M. Effect of age and gender on the activity of human hepatic Cyp3A. Biochem Pharmacol 1992; 44: 275-83.
25. Hunt CM, Westerkam WR, Stave M, Wilson J. Human hepatic cytochrome P4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992; 64: 189-99.
26. Gonzalez FJ, Skoda RC, Kimura S et al. Characterization of the common defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-46.
27. Lennard MS, Tucker GT, Silas JH, Woods HF. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 1986; 16: 435-47.
28. Kroemer HK, Mikus G, Kronbach J, Meyer UA, Eichelbaum M. In vitro characterization of the human cytochrome P450 involved in the polymorphic oxidation of propafenone. Clin Pharmacol Ther 1989; 45: 28-33.
29. Haefeli WE, Bargetzi MJ, Follath F, Meyer UA. Potent inhibition of cytochrome P450IID6 (debrisoquine 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 1990; 15: 776-79.
30. Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 1975; 18: 425-32.
31. Wood AJ, Vestal RE, Wilkinson GR, Branch RA, Shand DG. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther 1979; 26: 16-20.
32. Divoll M, Ameer B, Abernathy DJ, Greenblatt DJ. Age does not alter acetaminophen absorption. J Am Geriatr Soc 1982; 30: 240-44.
33. Murray TG, Chiang ST, Koepke HH, Walker BR. Renal disease, age and oxazepam kinetics. Clin Pharmacol Ther 1981; 30: 805-809.
34. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991; 1: 121-28.
35. Greenblatt DJ, Allen MD, Locniskar A, Harmatz JS, Shader RI. Larazepam kinetics in the elderly. Clin Pharmacol Ther 1979; 26: 103-13.
36. Baillie SP, Bateman DN, Coates PE, Woodhouse KW. Age and the pharmacokinetics of morphine. Age Ageing 1989; 18: 258-62.
37. Wynne HA, Cope LH, Herd B, Rawlins MD, James OFW, Woodhouse KW. The association of age and frailty with paracetamol conjugation in man. Age Ageing 1990; 19: 419-24.
38. Boyd E. Normal variability of weight of the adult human liver and spleen. Arch Pathol 1933; 16: 350-72.
39. Woodhouse KW, Wynne H. Age-related changes in hepatic function: implications for drug therapy. Drugs Aging 1992; 2: 243-55.
40. Swift CG, Homeida M, Halliwell M, Roberts CJ. Antipyrine disposition and liver size in the elderly. Eur J Clin Pharmacol 1978; 14: 149-52.
41. Wynne H, Cope L, Mutch E, Rawlins MD, Woodhouse KW, James OFW. The effect of age upon liver size and liver blood flow in man. Hepatology 1989; 9: 297-301.
42. Marchesini G, Bianchi GP, Fabbri A et al. Synthesis of urea after a protein-rich meal in normal man in relation to ageing. Age Ageing 1990; 19: 4-10.
43. Wynne H, Goudouvenous J, Adams P, Rawlins MD, James OFW, Woodhouse KW. Hepatic extraction of drugs: the effect of age using indocyanine green as a model substrate. Br J Clin Pharmacol 1990; 30: 634-37.
44. Kato R, Vassenelli P, Frontino G. Variation in the activity of liver microsomal drug metabolising enzymes in rats in relation to age. Biochem Pharmacol 1964; 12: 1037-51.
45. Vestal RE. Aging and determinants of hepatic drug clearance. Hepatology 1989; 9: 331-34.
46. Maloney AG, Schmucker DL, Vessey DS et al. The effects of ageing on the hepatic microsomal mixed-function oxidase system of male and female monkeys. Hepatology 1986; 6: 282-87.
47. Sutter MA, Wood WG, Williamson LS et al. Comparison of the hepatic mixed function oxidase system of young adults, and old non-human primates (Macco nemestrina). Biochem Pharmacol 1985; 34: 2983-87.
48. Woodhouse KW, Mutch E, Williams FM, Rawlins MD, James OFW. The effect of age on pathways of drug metabolism in human liver. Age Ageing 1984; 113: 328-34.
49. Schmucker DL, Woodhouse KW, Wang RK et al Effect of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharm Ther 1990; 48: 365-74.
50. Wynne H, Mutch E, James OFW, Wright IP, Rawlins MD, Woodhouse KW. The effect of age upon the affinity of microsomal monooxygenase enzymes for substrate in human liver. Age Ageing 1988; 17: 401-405.
51. Wynne H, Mutch E, James OFW, Fawlins MD, Woodhouse KW. Effect of age on monooxygenase enzyme kinetics in rat liver microsomes. Age Ageing 1987; 16: 153-58.
52. Vestal R, McGuire E, Tobin J, Andres R, Norris A, Mezey E. Aging and ethanol metabolism. Clin Pharmacol Ther 1977; 21: 343-54.
53. Williams FM, Wynne H, Woodhouse KW, Rawlins MD. Plasma aspirin esterase: the influence of old age and frailty. Age Ageing 1989; 18: 39-42.
54. Yelland C, Nicholson E, Wynne H, Woodhouse KW. The effect of age upon aspirin esterase activity in human liver. Age Ageing 1991; 20: 16-18.
55. Ali M, Nicholls PJ, Yoosuf A. The influence of old age and of renal failure on hepatic glucuronidation in the rat. Proceedings of the British Pharmaceutical Society, April 1979: 498-99.
56. Borghoff SJ, Birnhaum LS. Age-related changes in glucuronidation and deglucuronidation in liver, small intestine, lung and kidney of male Fischer rats. Drug Metab Dispos 1985; 13: 62-67.
57. Woodhouse KW, Herd B. The effect of age and gender on glucuronidation and sulphation in rat liver: a study using paracetamol as a model substrate. Arch Gerontol Geriatr 1993; 16: 111-15.
58. Herd B, Wynne H, Wright P, James OFW, Woodhouse KW. The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions. Br J Clin Pharmacol 1991; 32: 768-70.
59. Spearman ME, Leibman KC. Effects of aging on hepatic and pulmonary glutathione-S-transferase activities in male and female Fischer 344 rats. Biochem Pharmacol 1984; 33: 1309-13.
60. Sweeny DJ, Weiner M. Metabolism of acetaminophen in hepatocytes isolated from mice and rats of various ages. Drug Metab 1985; 13: 377-79.
61. Kato R, Takanaka A. Effects of phenobarbital on electron transport system. Oxidation and reduction of drugs in liver microsomes of rats of different ages. J Biochem (Tokyo) 1968; 63: 406-408.
62. Schmucker DL, Wang RK. Effects of aging and phenobarbital on the rat liver microsomal drug metabolising system. Mech Ageing Dev 1981; 15: 189-202.
63. Horback GJ, van Asten JG, van Bezooijen CFA. The influence of ageing on the induction of the mRNAs of rat liver cytochromes P450IIB1 and P450IIB2. Biochem Pharmacol 1990; 40: 529-33.
64. Beckett AH, Triggs EJ. Enzyme induction in man caused by smoking. Nature 1967; 216: 587-88.
65. Jenne J, Nagasawa H, McHugh R, MacDonald F, Wyse E. Decreased theophylline half-life in cigarette smokers. Life Sci 1975; 17: 195-98.
66. Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 1975; 18: 425-32.
67. Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR. Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 1979; 26: 8-15.
68. Mucklow JC, Fraser HS. The effects of age and smoking upon antipyrine metabolism. J Clin Pharmacol 1980; 9: 612-14.
69. Crowley JJ, Cusack BJ, Jue SG, Koup JR, Park BK, Vestal RE. Ageing and drug interactions II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy man. J Pharmacol Exp Ther 1988; 245: 513-23.
70. Bonde J, Pedersen LE, Bodtker S, Angelo HR, Svendsen TL, Kampmann JP. the influence of age and smoking on the elimination of disopyramide. Br J Clin Pharmacol 1985; 20: 453-58.
71. Salem SAM, Rajjayabun P, Shepherd AMM, Stevenson IH. Reduced induction of drug metabolism in the elderly. Age Ageing 1978; 7: 68-73.
72. Twum-Barima Y, Finnigan T, Habbash AI, Cape RD, Carruthers SF. Impaired enzyme induction of rifampicin in the elderly. Br J Clin Pharmacol 1984; 17: 595-97.
73. Pearson MW, Roberts CJC. Drug induction of hepatic enzymes in the elderly. Age Ageing 1984; 13: 313-164
74. Brodie MJ, Boobis AR, Bulpitt CJ, Davies DS. Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro. Eur J Clin Pharmacol 1981; 20: 39-46.
75. Boobis AR, Murray S, Seddon CE, Davies DS. In vitro studies of induction and inhibition of drug oxidation in man. Pharmacol Ther 1987; 33: 101-108.
76. George G, Wynne HA, Woodhouse KW. The association of age with the induction of drug metabolising enzymes in human monocytes. Age Ageing 1990; 19: 364-67.
77. George G, Wynne H, Woodhouse K. Age and the rate of induction in aryl hydrocarbon hydroxylase in isolated peripheral blood monocytes. Age Ageing 1991; 20: 421-23.
78. George G, Woodhouse K. Dose-dependent induction of the microsomal monooxygenase aryl hydrocarbon hydroxylase in isolated peripheral blood monocytes: the influence of age. Pharmacol Toxicol 1992; 71: 221-23.
79. George G, O'Mahony S, Woodhouse K. Age, smoking and the activity of the monooxygenase aryl hydrocarbon hydroxylase in isolated human peripheral blood monocytes.Age Ageing 1994; 23: 421-24.
80. Woodhouse KW, Wynne H, Baillie S, James OFW, Rawlins MD. Who are the frail elderly? Q J Med 1988; 68: 505-506.
81. Anderson KE. Nutritional effects on hepatic drug metabolism in the elderly. In: Prinsley DM, Sandstead HH eds. Nutrition and aging. New York: Alan R Liss Inc., 1990: 263-77.
82. Anderson KE, Conney AH, Kappas A. Nutrition and oxidative drug metabolism in man: relative influence of dietary lipids, carbohydrate and protein. Clin Pharmacol Ther 1979; 26: 493-501.
83. Holloway DE, Peterson FJ. Ascorbic acid in drug metabolism. In: Roe DA, Campbell JC eds. Drug and nutrients: the interactive effects. New York: Marcel Dekker Inc., 1984: 225-95.
84. Pantuck EJ, Pantuck CB, Garland WA et al. Stimulatory effect of Brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979; 25: 88-95.
85. Bienia R, Ratcliff S, Barbour GL, Kummer M. Malnutrition in the hospitalised geriatric patient. J Am Geriatr Soc 1982; 30: 433-36.
86. Bistrian BR, Blackburn GL, Vitale J, Cochran D, Naylor J. Prevalence of malnutrition in general medical patients. J Am Med Assoc 1976; 235: 1567-70.
87. Summerbell J, Williams FM, Hankey CR, Wynne HA. The effect of age and frailty upon paraoxonase and aryl esterase activities and their response to a period of nutritional supplementation. In: Woodhouse KW, O'Mahony MS eds. Drug metabolism, liver injury and ageing. Leiden: Eurage, 1991: 23-32.
88. O'Mahoney MS, George G, Westlake H, Woodhouse K. Plasma aspirin esterase activity in elderly patients undergoing elective hip replacement and with fractured neck of femur. Age Ageing 1994; 23: 338-41.